August 13 AFP Geneva, August 11 reported that the World Health Organization announced on the 11th, that three drugs to conduct large-scale international trials to determine whether they can alleviate the condition of patients hospitalized with new coronary pneumonia.
Researchers will test thousands of volunteer patients at more than 600 hospitals in 52 countries to test the efficacy of artesunate, immatini and infliximab, the report said. “Finding more effective and convenient treatments for patients with new coronary pneumonia remains a key need,” said WHO Director-General Tandsey.
According to the report, artesunate is a drug for severe malaria, imatini is a drug for specific cancers, and infliximab can treat immune system diseases such as Crohn’s disease and rheumatoid arthritis.
WHO says the collaborative study, which has spread across dozens of countries, allows trials to use a single program to evaluate multiple treatments to make convincing estimates of the effects of a single drug on mortality.
The drugs were selected by an independent panel of experts because they have the potential to reduce the risk of death in hospital with new coronary pneumonia, the report said.
The report also said the experimental drug was donated by drug makers and is now being shipped to the relevant hospitals.
Reported that the WHO New Coronavirus Treatment Advisory Group recommended an assessment of the anti-inflammatory properties of artesunate, which has been widely used for more than 30 years to treat malaria and other parasitic diseases and is considered very safe.